NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025
NeurAxis (NYSE American: NRXS), a medical technology company focused on neuromodulation therapies for chronic conditions in children and adults, has scheduled its first quarter 2025 financial results announcement for Monday, May 12, 2025. The company will release its financial results for the period ended March 31, 2025, before the market opens.
A conference call to discuss the results will be held the same day at 9:00 AM ET. Interested parties can access the call through a live webcast on the company's investor relations website or via dial-in registration. A replay will be available on the company's website following the call.
NeurAxis (NYSE American: NRXS), un'azienda di tecnologia medica specializzata in terapie di neuromodulazione per condizioni croniche in bambini e adulti, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per lunedì 12 maggio 2025. La società pubblicherà i risultati finanziari relativi al periodo terminato il 31 marzo 2025, prima dell'apertura del mercato.
Lo stesso giorno, alle 9:00 AM ET, si terrà una conference call per discutere i risultati. Gli interessati potranno accedere alla chiamata tramite una diretta web sul sito dedicato agli investitori dell'azienda o registrandosi per la partecipazione telefonica. Una registrazione sarà disponibile sul sito aziendale dopo la chiamata.
NeurAxis (NYSE American: NRXS), una empresa de tecnología médica centrada en terapias de neuromodulación para condiciones crónicas en niños y adultos, ha programado el anuncio de resultados financieros del primer trimestre de 2025 para el lunes 12 de mayo de 2025. La compañía publicará los resultados financieros correspondientes al periodo finalizado el 31 de marzo de 2025, antes de la apertura del mercado.
Ese mismo día, a las 9:00 AM ET, se realizará una llamada conferencia para discutir los resultados. Las personas interesadas podrán acceder a la llamada a través de una transmisión en vivo en el sitio web de relaciones con inversionistas de la compañía o mediante registro para participar por teléfono. Una grabación estará disponible en el sitio web de la empresa después de la llamada.
NeurAxis (NYSE American: NRXS)는 어린이와 성인의 만성 질환을 위한 신경조절 치료에 중점을 둔 의료기술 회사로, 2025년 1분기 재무실적 발표를 2025년 5월 12일 월요일로 예정하고 있습니다. 회사는 2025년 3월 31일 종료된 기간의 재무실적을 시장 개장 전에 발표할 예정입니다.
같은 날 오전 9시 ET에 실적 관련 컨퍼런스 콜이 진행됩니다. 관심 있는 분들은 회사 투자자 관계 웹사이트에서 생중계 웹캐스트를 통해 접속하거나 전화 등록을 통해 참여할 수 있습니다. 콜 종료 후 회사 웹사이트에서 재청취가 가능합니다.
NeurAxis (NYSE American : NRXS), une entreprise de technologie médicale spécialisée dans les thérapies de neuromodulation pour les affections chroniques chez les enfants et les adultes, a programmé l'annonce des résultats financiers du premier trimestre 2025 pour le lundi 12 mai 2025. La société publiera les résultats financiers pour la période close au 31 mars 2025, avant l'ouverture des marchés.
Une conférence téléphonique pour discuter des résultats aura lieu le même jour à 9h00 ET. Les personnes intéressées pourront accéder à l'appel via une webdiffusion en direct sur le site des relations investisseurs de la société ou via une inscription pour la participation par téléphone. Un replay sera disponible sur le site de la société après la conférence.
NeurAxis (NYSE American: NRXS), ein Medizintechnologieunternehmen, das sich auf Neuromodulationstherapien für chronische Erkrankungen bei Kindern und Erwachsenen spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für Montag, den 12. Mai 2025 terminiert. Das Unternehmen wird die Finanzergebnisse für den Zeitraum bis zum 31. März 2025 vor Markteröffnung veröffentlichen.
Am selben Tag findet um 9:00 Uhr ET eine Telefonkonferenz zur Besprechung der Ergebnisse statt. Interessierte können über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens teilnehmen oder sich für die Einwahl registrieren. Eine Aufzeichnung wird nach der Telefonkonferenz auf der Website verfügbar sein.
- None.
- None.
Financial results to be released before market open; Conference call to be conducted at 9:00 a.m. Eastern Time
CARMEL, Ind., May 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its first quarter 2025, for the period ended March 31, 2025, on Monday, May 12, 2025, before market open. The Company has scheduled a conference call for the same day, Monday, May 12, 2025, at 9:00 am ET to review the results.
Conference Call Details
Date and Time: Monday, May 12, 2024, at 9:00am ET
Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/hn59d9cm. For participants listening through the webcast, questions can be sent in through the portal using the “Ask a Question” link or by emailing questions to NRXS@lythampartners.com.
Call-in Information: Interested parties can also access the live conference call by initially registering at the following link. Upon completion of the registration link, call-in participants will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.
Replay: A webcast replay will be available in the Investor Relations section of the Company's website at https://ir.neuraxis.com/ or https://edge.media-server.com/mmc/p/hn59d9cm.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
FAQ
When will NeurAxis (NRXS) release its Q1 2025 earnings?
What time is the NeurAxis (NRXS) Q1 2025 earnings call?
How can I access the NeurAxis (NRXS) Q1 2025 earnings call?
What does NeurAxis (NRXS) company do?
